Phase 1 Study of Anito-cel, a d-Domain BCMA CAR T Cell for Refractory or Recurrent Myeloma

A study published in the New England Journal of Medicine in September 2026 investigated the safety and efficacy of an experimental CAR T cell therapy called Anito-cel in patients with refractory or recurrent myeloma. Anito-cel is an innovative cell therapy that utilizes a d-domain and targets the BCMA antigen found on the surface of myeloma cells. This was a Phase 1 clinical trial, meaning it represented the first testing of this therapy in humans with emphasis on safety. The study was published in a prestigious medical journal and represents progress in treating patients with aggressive myeloma that does not respond to standard treatments.